Virax Biolabs Files 6-K for FY25 Q2 Results
Ticker: VRAX · Form: 6-K · Filed: Nov 20, 2024 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-K, diagnostics
TL;DR
Virax Biolabs dropped its Q2 FY25 results on 11/20/24. Check the 6-K for deets.
AI Summary
Virax Biolabs Group Ltd filed a Form 6-K on November 20, 2024, reporting its financial results for the fiscal year ending March 31, 2025, and the second quarter of fiscal year 2025. The company is based in the United Kingdom and operates in the in vitro & in vivo diagnostic substances sector.
Why It Matters
This filing provides investors with updated financial information and operational details for Virax Biolabs Group Ltd, crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes that would inherently increase risk.
Key Players & Entities
- Virax Biolabs Group Ltd (company) — Registrant
- 001-41440 (company) — SEC File Number
- 241480301 (company) — Film Number
- 2835 (company) — Standard Industrial Classification Code
- November 2024 (date) — Reporting Period
- March 31, 2025 (date) — Fiscal Year End
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of November 2024, reporting on fiscal year 2025 Q2 results.
What is the company's primary business sector?
The company's Standard Industrial Classification is 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' with the code 2835.
When is Virax Biolabs Group Ltd's fiscal year end?
The company's fiscal year end is March 31.
What is the company's principal executive office address?
The principal executive offices are located at BioCity Glasgow, Bo-Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.
Has the company changed its name previously?
Yes, the former company name was Virax Biolabs (Cayman) Ltd, with a date of name change on September 30, 2021.
Filing Stats: 282 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-11-20 16:03:25
Filing Documents
- 6-k_fy2025_q2_results.htm (6-K) — 28KB
- vrax-ex99_1.htm (EX-99.1) — 1145KB
- vrax-ex99_2.htm (EX-99.2) — 150KB
- 0000950170-24-129224.txt ( ) — 1324KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: November 20, 2024 By: /s/ James Foster James Foster, Chief Executive Officer